Bachem Holding AG (BCHMY)
Healthcare · PNK
Price as at 30 Sept 2026, 16:23 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Bachem Holding AG trades at $9.54, which is 16% above the $8.02 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 51 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 38.1 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
BCHMY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.115 | 1 |
| 2025 | $0.103 | 2 |
| 2024 | $0.087 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
BCHMY passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
BCHMY peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Bachem Holding AG (BCHMY) undervalued?
Against our fair value estimate of $8.02, BCHMY at $9.54 is 16% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is BCHMY's P/E ratio?
BCHMY trades at 38.1 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Bachem Holding AG (BCHMY) pay a dividend?
Yes. Bachem Holding AG yields 1.26% at the current share price. It has paid $0.115 per share over the trailing twelve months. It has paid a dividend in each of the last 2 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its BCHMY data?
Fundamentals for BCHMY come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:23 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BCHMY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.